Synopsis：Risedronate can combine with hydroxyapatite in bone and inhibit bone resorption. At the cellular level, the product inhibits osteoclasts. Osteoclasts usually exist on the surface of bone, but have no obvious absorption activity. This product is suitable for the treatment and prevention of osteoporosis in postmenopausal women.
Structural formula:
Properties
Summary
Risedronate can combine with hydroxyapatite in bone and inhibit bone resorption. At the cellular level, the product inhibits osteoclasts. Osteoclasts usually exist on the surface of bone, but have no obvious absorption activity. This product is suitable for the treatment and prevention of osteoporosis in postmenopausal women.
Manufacturing
